<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756509</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107DDE06</org_study_id>
    <secondary_id>2008-000358-11</secondary_id>
    <nct_id>NCT00756509</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib</brief_title>
  <official_title>An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter, single-arm, exact binomial single-stage, phase II trial is&#xD;
      to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic&#xD;
      gastrointestinal stromal tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 29, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective tumor response rate based on RECIST criteria (complete response (CR) and partial response PR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to overall response (PR or CR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS) during the first 6 months using RECIST criteria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>population pharmacokinetics of Nilotinib</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nilotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>800 mg/d orally</description>
    <arm_group_label>nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histologically confirmed diagnosis of GIST that is unresectable and/or metastatic and&#xD;
             therefore not amenable to surgery or combined modality with curative intent prior to&#xD;
             or at Visit 1&#xD;
&#xD;
          -  At least one measurable site of disease on CT/MRI scan at Visit 1, as defined by&#xD;
             RECIST criteria (see Post Text Suppl 3 for details) The scans should be at maximum 2&#xD;
             weeks old. New scans are only required as baseline scans if they are older then&#xD;
             approx. 2 weeks.&#xD;
&#xD;
          -  WHO Performance Status of 0, 1 or 2&#xD;
&#xD;
          -  Patients must have the following laboratory values (≥ LLN (lower limit of normal) or&#xD;
             corrected to within normal limits with supplements prior to the first dose of study&#xD;
             medication.):&#xD;
&#xD;
               1. Potassium ≥ LLN,&#xD;
&#xD;
               2. Magnesium ≥ LLN,&#xD;
&#xD;
               3. Phosphorus ≥ LLN,&#xD;
&#xD;
               4. Total calcium (corrected for serum albumin) ≥ LLN&#xD;
&#xD;
          -  Patients must have normal organ, electrolyte, and marrow function as defined below:&#xD;
&#xD;
               1. Absolute Neutrophil Count (ANC) ≥ 1.5x 109/L;&#xD;
&#xD;
               2. Platelets ≥ 100 x 109/L;&#xD;
&#xD;
               3. ALT and AST ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if considered due&#xD;
                  to tumor;&#xD;
&#xD;
               4. Alkaline phosphatase ≤ 2.5 x ULN unless considered due to tumor;&#xD;
&#xD;
               5. Serum bilirubin ≤ 1.5 x ULN;&#xD;
&#xD;
               6. Serum lipase and amylase ≤ 1.5 x ULN;&#xD;
&#xD;
               7. Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min.&#xD;
                  (calculated creatinine clearance using Cockroft formula is acceptable)&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with nilotinib&#xD;
&#xD;
          -  Treatment with any cytotoxic and/or investigational cytotoxic drug ≤ 4 weeks (6 weeks&#xD;
             for nitrosurea or mitomycin C) prior to Visit 1 with the exception of imatinib&#xD;
             targeted therapy as an adjuvant therapy&#xD;
&#xD;
          -  Prior or concomitant malignancies requiring active treatment other than GIST with the&#xD;
             exception of previous or concomitant basal cell skin cancer, previous cervical&#xD;
             carcinoma in situ&#xD;
&#xD;
          -  Impaired cardiac function at including any one of the following:&#xD;
&#xD;
               1. LVEF &lt; 45% or below the institutional LLN range (whichever is higher) as&#xD;
                  determined by echocardiogram at Visit 1&#xD;
&#xD;
               2. Complete left bundle branch block&#xD;
&#xD;
               3. Use of a ventricular paced cardiac pacemaker&#xD;
&#xD;
               4. Congenital long QT syndrome or family history of long QT syndrome&#xD;
&#xD;
               5. History of or presence of significant ventricular or atrial tachyarrhythmias&#xD;
&#xD;
               6. Clinically significant resting bradycardia (&lt; 50 beats per minute)&#xD;
&#xD;
               7. QTc &gt; 450 msec on screening ECG (using the QTcF formula). If QTc &gt; 450 msec and&#xD;
                  electrolytes are not within normal ranges (electrolytes should be corrected and&#xD;
                  then the patient rescreened for QTc.&#xD;
&#xD;
               8. Right bundle branch block plus left anterior hemiblock, bifascicular block&#xD;
&#xD;
               9. Myocardial infarction within 12 months prior to Visit 1&#xD;
&#xD;
              10. Other clinically significant heart disease (e.g., unstable angina, congestive&#xD;
                  heart failure or uncontrolled hypertension,)&#xD;
&#xD;
          -  Patients with severe and/or uncontrolled concurrent medical disease that in the&#xD;
             opinion of the investigator could cause unacceptable safety risks or compromise&#xD;
             compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI&#xD;
             disease that may significantly alter the absorption of the study drugs, uncontrolled&#xD;
             diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unresectable or metastatic GIST</keyword>
  <keyword>1st. line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
    <ipd_url>https://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

